Alexion Pharma Inc. (ALXN) announced data showing the effects of Eculizumab Therapy in patients with Paroxysmal Nocturnal Hemoglobinuria receiving concurrent immunosuppressive therapy for Bone Marrow Insufficiency. The company said the study showed that Soliris reduced hemolysis and transfusion requirements, and improved measures of fatigue, when added to ongoing immunosuppressive therapy in patients with both paroxysmal nocturnal hemoglobinuria and bone marrow insufficiency, including aplastic anemia.
In the study, patients with concomitant bone marrow insufficiency and paroxysmal nocturnal hemoglobinuria treated with immunosuppressive therapy, prior to addition of Soliris, continued to suffer increased hemolysis and fatigue, contributing to paroxysmal nocturnal hemoglobinuria-related morbidities.
The study also showed that patients with bone marrow insufficiency and paroxysmal nocturnal hemoglobinuria, in which Soliris treatment was added to ongoing immunosuppressive therapy, experienced a substantial reduction in hemolysis and fatigue, and subsequent morbidities.
For comments and feedback: editorial@rttnews.com